Dr. Peterson appointed to ICMS Board
International Cellular Medicine Society provides oversight in stem cell research
Dr. Noel Peterson, has recently been appointed a member of the Institutional Review Board of the International Cellular Medicine Society (ICMS). He is recognized as an expert in the field of regenerative orthopedics, and has specialized in regenerative medicine and Prolotherapy since 1999, Platelet Rich Plasma (PRP) since 2006, and Adult Stem Cell therapies since 2012.
The mission of the ICMS is:
- To provide education, oversight and best practices to assure patient safety, ethical conduct and effective treatment,
- To build a comprehensive registry of adult stem cell procedures and prove 20 year tracking of patient outcomes, complications
- To provide clinical and laboratory guidelines to assure that physicians and clinics worldwide are using best practices to collect process and re-implant adult stem cells in patients, and
- To provide an international Institutional Review Board to classify, monitor and advance safe and effective cell lines and procedures.
Dr. Peterson is Certified in Prolotherapy by the American Association of Orthopedic Medicine (AAOMED.org).
He is a long standing member of the International Cellular Medicine Society, where he serves on the ICMS Institutional Review Board. At Oregon Regenerative Medicine in Lake Oswego, Oregon, doctors provide a viable alternative to joint replacement surgery by using an adult stem cell grafting procedure to treat advanced osteoarthritis. Doctors harvest and concentrate Mesenchymal stem cells (AD-SVF ) from adult patients. This tissue is grafted back into the same patient for the treatment of moderate to severe osteoarthritis of the major joints. This cell-rich bioactive matrix contains as much as 500 to 1000 times the concentration of Mesenchymal stem cells and progenitor cells when compared to bone marrow. AD-SVF additionally provides an extensive bioactive extracellular matrix, which is considered essential for successful tissue repair grafts. We complement our AD-SVF implants with the addition of high density PRP, which provides additional growth factors, cytokines, chemokines and bioactive scaffolding, all of which enhance the microenvironment for repair and healing.
In addition to his active practice, Dr. Peterson has been principal investigator on two IRB approved cancer research protocols in collaboration with Legacy-Good Samaritan Hospital’s Comprehensive Cancer Center and Kaiser Pemanente hospital. He has also been principal investigator two IRB approved protocols on cellular regenerative medicine, and provides physician trainings in cost-effective protocols for harvesting platelet rich plasma. His PRP protocols were recently published in The Journal of Prolotherapy.
Information on the ICMS can be found at www.cellmedicinesociety.org.